Ablative therapy in oligometastatic non-small cell lung cancer-an editorial on recent evidence.
作者信息
Niglas Mark, Cheung Patrick
机构信息
Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto, Ontario, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
出版信息
J Thorac Dis. 2018 Jan;10(1):138-140. doi: 10.21037/jtd.2017.12.119.
Abstract
摘要
相似文献
1
Ablative therapy in oligometastatic non-small cell lung cancer-an editorial on recent evidence.寡转移非小细胞肺癌的消融治疗——基于近期证据的一篇社论
J Thorac Dis. 2018 Jan;10(1):138-140. doi: 10.21037/jtd.2017.12.119.
2
Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.寡转移非小细胞肺癌的消融治疗。
Clin Lung Cancer. 2017 Nov;18(6):595-606. doi: 10.1016/j.cllc.2017.03.002. Epub 2017 Mar 14.
3
Local ablative radiotherapy for oligometastatic non-small cell lung cancer.寡转移非小细胞肺癌的局部消融放疗
Radiat Oncol J. 2019 Sep;37(3):149-155. doi: 10.3857/roj.2019.00514. Epub 2019 Sep 30.
4
Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease.立体定向消融体部放疗用于寡转移和寡进展性疾病。
Transl Lung Cancer Res. 2019 Feb;8(1):97-106. doi: 10.21037/tlcr.2018.09.21.
5
6
Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.根治性治疗的同步与异时寡转移非小细胞肺癌的长期预后
BMC Cancer. 2016 Jun 2;16:348. doi: 10.1186/s12885-016-2379-x.
7
The current state of oligometastatic and oligoprogressive non-small cell lung cancer.寡转移和寡进展性非小细胞肺癌的现状
J Thorac Dis. 2018 Aug;10(Suppl 21):S2537-S2544. doi: 10.21037/jtd.2018.07.19.
8
Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.局部消融治疗在寡转移和寡进展性非小细胞肺癌患者中的作用。
J Thorac Oncol. 2017 Feb;12(2):179-193. doi: 10.1016/j.jtho.2016.10.012. Epub 2016 Oct 22.
9
Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients.立体定向消融放疗对非小细胞肺癌寡转移患者肺转移病灶的临床疗效
Clin Oncol (R Coll Radiol). 2016 Jan;28(1):13-20. doi: 10.1016/j.clon.2015.08.011. Epub 2015 Sep 15.
10
Risk factors and management of oligometastatic non-small cell lung cancer.寡转移非小细胞肺癌的危险因素与管理
Ther Adv Respir Dis. 2016 Aug;10(4):338-48. doi: 10.1177/1753465816642636. Epub 2016 Apr 8.
引用本文的文献
1
Lung-molGPA Index Predicts Survival Outcomes of Non-Small-Cell Lung Cancer Patients with Synchronous or Metachronous Brain Metastases.肺分子GPA指数可预测非小细胞肺癌伴同步或异时性脑转移患者的生存结局。
Onco Targets Ther. 2020 Sep 4;13:8837-8844. doi: 10.2147/OTT.S255478. eCollection 2020.
本文引用的文献
1
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.局限性转移性非小细胞肺癌的巩固性放疗：一项 2 期随机临床试验。
JAMA Oncol. 2018 Jan 11;4(1):e173501. doi: 10.1001/jamaoncol.2017.3501.
2
Stereotactic radiotherapy in oligometastatic cancer.寡转移癌的立体定向放射治疗。
Chin Clin Oncol. 2017 Sep;6(Suppl 2):S16. doi: 10.21037/cco.2017.06.20.
3
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
4
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.一线全身治疗后无进展的寡转移性非小细胞肺癌患者的局部巩固治疗与维持治疗或观察比较：一项多中心、随机、对照、2期研究
Lancet Oncol. 2016 Dec;17(12):1672-1682. doi: 10.1016/S1470-2045(16)30532-0. Epub 2016 Oct 24.
5
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
6
The evolutionary history of lethal metastatic prostate cancer.致死性转移性前列腺癌的进化史。
Nature. 2015 Apr 16;520(7547):353-357. doi: 10.1038/nature14347. Epub 2015 Apr 1.
7
An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer.寡转移非小细胞肺癌治疗后结局及预后因素的个体患者数据荟萃分析
Clin Lung Cancer. 2014 Sep;15(5):346-55. doi: 10.1016/j.cllc.2014.04.003. Epub 2014 May 15.
8
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.克唑替尼与化疗用于治疗晚期 ALK 阳性肺癌。
N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1.
9
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.厄洛替尼对比化疗用于治疗晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（OPTIMAL、CTONG-0802）：一项多中心、开放标签、随机、III 期研究。
Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23.
10
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.吉非替尼或化疗用于治疗具有突变型 EGFR 的非小细胞肺癌。
N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.
Zotero 插件